S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Bolt Biotherapeutics Stock Forecast, Price & News

+0.27 (+3.00%)
(As of 11/30/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
323,342 shs
Average Volume
219,664 shs
Market Capitalization
$345.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BOLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bolt Biotherapeutics logo

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.


Bolt Biotherapeutics (NASDAQ:BOLT) Rating Reiterated by Jonestrading
November 24, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$230 thousand


Net Income
$-60.73 million
Pretax Margin




Free Float
Market Cap
$345.63 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.99 out of 5 stars

Medical Sector

622nd out of 1,390 stocks

Pharmaceutical Preparations Industry

290th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Bolt Biotherapeutics (NASDAQ:BOLT) Frequently Asked Questions

Is Bolt Biotherapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bolt Biotherapeutics stock.
View analyst ratings for Bolt Biotherapeutics
or view top-rated stocks.

When is Bolt Biotherapeutics' next earnings date?

Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Bolt Biotherapeutics

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.63) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.75) by $0.12. The business earned $0.75 million during the quarter, compared to the consensus estimate of $1.50 million.
View Bolt Biotherapeutics' earnings history

What price target have analysts set for BOLT?

5 equities research analysts have issued 12 month target prices for Bolt Biotherapeutics' stock. Their forecasts range from $33.00 to $45.00. On average, they expect Bolt Biotherapeutics' share price to reach $41.00 in the next year. This suggests a possible upside of 342.3% from the stock's current price.
View analysts' price targets for Bolt Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bolt Biotherapeutics' key executives?

Bolt Biotherapeutics' management team includes the following people:
  • Dr. Randall C. Schatzman, CEO & Director (Age 66, Pay $706.05k)
  • Mr. William P. Quinn, Chief Financial Officer (Age 50, Pay $454.69k)
  • Dr. David Dornan Ph.D., Chief Scientific Officer (Age 43, Pay $422.5k)
  • Mr. Grant Yonehiro, Chief Bus. Officer (Age 57, Pay $434.07k)
  • Dr. Edith A. Perez M.D., Chief Medical Officer (Age 64, Pay $607.49k)
  • Dr. Edgar G. Engleman, Founder, Sec. & Director (Age 75)
  • Mr. Wesley Burwell, VP & Head of HR

What other stocks do shareholders of Bolt Biotherapeutics own?

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (7.72%), Rock Springs Capital Management LP (4.42%), BlackRock Inc. (3.91%), Suvretta Capital Management LLC (3.56%), Goldman Sachs Group Inc. (1.19%) and Geode Capital Management LLC (0.93%). Company insiders that own Bolt Biotherapeutics stock include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends for Bolt Biotherapeutics

Which major investors are selling Bolt Biotherapeutics stock?

BOLT stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Morgan Stanley, Citadel Advisors LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Bolt Biotherapeutics
or view top insider-selling stocks.

Which major investors are buying Bolt Biotherapeutics stock?

BOLT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Suvretta Capital Management LLC, Geode Capital Management LLC, Millennium Management LLC, Point72 Asset Management L.P., Rock Springs Capital Management LP, Dupont Capital Management Corp, and Bank of New York Mellon Corp. Company insiders that have bought Bolt Biotherapeutics stock in the last two years include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP, and William P Quinn.
View insider buying and selling activity for Bolt Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $9.27.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics has a market capitalization of $345.63 million and generates $230 thousand in revenue each year. The company earns $-60.73 million in net income (profit) each year or ($16.99) on an earnings per share basis.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 65 workers across the globe.

What is Bolt Biotherapeutics' official website?

The official website for Bolt Biotherapeutics is www.boltbio.com.

Where are Bolt Biotherapeutics' headquarters?

Bolt Biotherapeutics is headquartered at 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-665-9295 or via email at [email protected].

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.